Abeona Therapeutics (ABEO) to Release Quarterly Earnings on Monday

Abeona Therapeutics (NASDAQ:ABEO) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $21.71 million for the quarter.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.11. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Abeona Therapeutics Price Performance

NASDAQ ABEO opened at $6.26 on Friday. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.27. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.32. The company has a market capitalization of $320.26 million, a PE ratio of -4.93 and a beta of 1.55. The firm’s 50 day moving average is $6.21 and its 200-day moving average is $5.69.

Insiders Place Their Bets

In related news, CEO Vishwas Seshadri sold 69,420 shares of the firm’s stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total value of $406,801.20. Following the completion of the transaction, the chief executive officer directly owned 1,234,341 shares of the company’s stock, valued at approximately $7,233,238.26. This trade represents a 5.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joseph Walter Vazzano sold 25,411 shares of the firm’s stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total value of $148,908.46. Following the sale, the chief financial officer directly owned 479,168 shares of the company’s stock, valued at $2,807,924.48. This represents a 5.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold 239,626 shares of company stock valued at $1,476,027 in the last ninety days. 6.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Creative Planning lifted its holdings in Abeona Therapeutics by 43.0% during the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 4,305 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Abeona Therapeutics by 49.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock valued at $954,000 after purchasing an additional 66,422 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Abeona Therapeutics by 129.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock valued at $6,282,000 after purchasing an additional 623,243 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Wall Street Analyst Weigh In

ABEO has been the topic of a number of recent research reports. Wall Street Zen downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 15th. Alliance Global Partners reiterated a “buy” rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Oppenheimer began coverage on shares of Abeona Therapeutics in a research note on Monday, June 2nd. They issued an “outperform” rating and a $19.00 target price for the company. Stifel Nicolaus decreased their target price on shares of Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, May 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research note on Monday, July 14th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Abeona Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $19.25.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.